Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib Prior to Tumor Reductive Surgery in Ovarian Cancer
NCT02659241Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2016
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Change in level of deoxyribonucleic acid (DNA) copy number in p53-related pathways, Change in level of mutation in p53-related pathways and 2 more. Started Feb 2016; status: active, not recruiting.
02
Drugs
adavosertib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02659241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659241.